C12N 2760/16211
Influenzavirus b, i.e. influenza b virus
Official title: Influenzavirus B, i.e. influenza B virus
C12N2760/16211 (Influenzavirus b, i.e. influenza b virus) appears on 500 US grants and 830 published applications in this corpus.
Search patents in C12N- Granted patents
- 500
- Published applications
- 830
- Assignees
- 346
- Inventors
- 1,367
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 2 | 0 |
| 1978 | 2 | 0 |
| 1979 | 2 | 0 |
| 1980 | 2 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 4 | 0 |
| 1997 | 8 | 0 |
| 1998 | 5 | 0 |
| 1999 | 4 | 0 |
| 2000 | 4 | 0 |
| 2001 | 3 | 1 |
| 2002 | 4 | 1 |
| 2003 | 5 | 8 |
| 2004 | 3 | 16 |
| 2005 | 5 | 13 |
| 2006 | 3 | 20 |
| 2007 | 5 | 22 |
| 2008 | 9 | 31 |
| 2009 | 16 | 46 |
| 2010 | 6 | 43 |
| 2011 | 16 | 41 |
| 2012 | 21 | 46 |
| 2013 | 30 | 39 |
| 2014 | 26 | 45 |
| 2015 | 29 | 34 |
| 2016 | 37 | 46 |
| 2017 | 18 | 36 |
| 2018 | 33 | 33 |
| 2019 | 31 | 47 |
| 2020 | 29 | 44 |
| 2021 | 21 | 30 |
| 2022 | 27 | 41 |
| 2023 | 22 | 39 |
| 2024 | 21 | 52 |
| 2025 | 22 | 31 |
| 2026 | 13 | 25 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/16234Use of virus or viral component as vaccineIndexing code393
- C12N 2760/16222New viral proteins or individual genes, new structural or functional aspects ofIndexing code182
- C12N 2760/16251Methods of production or purification of viral materialIndexing code112
- C12N 2760/16261Methods of inactivation or attenuationIndexing code64
- C12N 2760/16271Demonstrated in vivo effectIndexing code59
- C12N 2760/16223Virus like particles [vlp]Indexing code36
- C12N 2760/16241Use of virus, viral particle or viral elements as a vectorIndexing code32
- C12N 2760/16221Viruses as suchIndexing code30
All 12 subgroupsShow fewer
Recent patents
- Mutant influenza B/Victoria lineage virus hemagglutinin proteins6 Oct 2026US 12,752,001 B2ModernaTX, Inc.
- Coronavirus and influenza compositions and methods for using them25 Aug 2026US 12,714,744 B2
- Vaccination of immunocompromised subjects4 Aug 2026US 12,697,382 B2Seqirus UK Limited
- MDCK suspension cell lines in serum-free, chemically-defined media for vaccine production30 Jun 2026US 12,667,612 B2Fujifilm Biosciences Inc.
- Compositions and methods for membrane protein structure determination12 May 2026US 12,624,092 B2The Regents of the University of Michigan
- Influenza virus vaccines24 Sep 2026US 2026/0284174 A1Glaxosmithkline Biologicals SA
- Vaccination using high-density microprojection array patch17 Sep 2026US 2026/0273256 A1Vaxxas Pty Limited
- Influenza b virus mutants and uses therefor10 Sep 2026US 2026/0263586 A1FluGen, Inc.
- Nucleic acid influenza vaccines and respiratory virus combination vaccines27 Aug 2026US 2026/0248903 A1ModernaTX, Inc.
- Lipid particle compositions and methods of use thereof30 Jul 2026US 2026/0216313 A1Pfizer Inc.
Most cited
By later US patents
- Nucleic acid vaccines165US 9,872,900 B2ModernaTX, Inc. · 2018
- Viral liposome particle151US 4,261,975 AMerck & Co., Inc. · 1981
- Vaccine comprising a baculovirus produced influenza hemagglutinin protein fused to a second protein146US 5,858,368 AProtein Sciences Corporation · 1999
- Method for producing influenza hemagglutinin multivalent vaccines using baculovirus139US 5,762,939 AMg-Pmc, LLC · 1998
- Expression of influenza a M2 protein in baculovirus108US 5,290,686 AThe United States of America as represented by the Department of Health and Human Services · 1994